Anshan Hifichem Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Huixiang Xu

Chief Executive Officer (CEO)

CN¥797.2k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	18yrs
Participación del CEO	45.3%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	7.4yrs

Actualizaciones recientes de la dirección

Recent updates

There's Reason For Concern Over Anshan Hifichem Co., Ltd.'s (SZSE:300758) Massive 30% Price Jump

May 27

Anshan Hifichem (SZSE:300758) Could Be Struggling To Allocate Capital

May 06

With Anshan Hifichem Co., Ltd. (SZSE:300758) It Looks Like You'll Get What You Pay For

Feb 28

CEO

Huixiang Xu (53 yo)

18yrs

Permanencia

CN¥797,219

Compensación

Mr. Huixiang Xu serves as Chairman and General Manager of Anshan Hifichem Co., Ltd and has been its Director since June 12, 2006.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Huixiang Xu	Chairman & GM	18yrs	CN¥797.22k	45.31% CN¥ 1.9b
Zhi Qiao	Deputy GM & Non-Independent Director	5.1yrs	CN¥533.06k	0.26% CN¥ 11.1m
Xuebo Qi	Deputy GM & Director	18yrs	CN¥427.60k	0.47% CN¥ 20.0m
Zhidong Liu	Non-Employee Supervisor	9.1yrs	sin datos	0.061% CN¥ 2.6m
Dongbo Li	Staff Supervisor	12.8yrs	sin datos	0.0057% CN¥ 243.0k
Sukun Wang	Non-Employee Supervisor	6.1yrs	sin datos	0.13% CN¥ 5.4m
Zhiqun Zhang	Non-Independent Director	8.8yrs	CN¥370.67k	0.10% CN¥ 4.4m
Xiaodong Liang	Independent Director	3yrs	CN¥96.00k	sin datos
Wenyong Duan	Non-Independent Director	7.4yrs	sin datos	sin datos
Qi Wang	Independent Director	1.7yrs	CN¥96.00k	sin datos
Yonghua Wang	Independent Director	1.7yrs	CN¥96.00k	sin datos

7.4yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de 300758 se considera experimentada (7.3 años de antigüedad promedio).

Anshan Hifichem Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024

Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024

Insufficient new directors

High number of new directors

Anshan Hifichem Co., Ltd. Announces Directorate Changes

High number of new directors

Recent updates

There's Reason For Concern Over Anshan Hifichem Co., Ltd.'s (SZSE:300758) Massive 30% Price Jump

Anshan Hifichem (SZSE:300758) Could Be Struggling To Allocate Capital

First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.04 loss in 1Q 2023)

New major risk - Share price stability

Anshan Hifichem Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

With Anshan Hifichem Co., Ltd. (SZSE:300758) It Looks Like You'll Get What You Pay For

Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024

New minor risk - Share price stability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024

New major risk - Revenue and earnings growth

Anshan Hifichem Co., Ltd. to Report Fiscal Year 2023 Results on Feb 29, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: CN¥0.021 (vs CN¥0.009 loss in 3Q 2022)

New minor risk - Share price stability

Anshan Hifichem Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.007 (vs CN¥0.002 in 2Q 2022)

First quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.06 profit in 1Q 2022)

Insufficient new directors

High number of new directors

Third quarter 2022 earnings released: CN¥0.009 loss per share (vs CN¥0.094 profit in 3Q 2021)

Anshan Hifichem Co., Ltd. Announces Directorate Changes

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.002 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Anshan Hifichem Co., Ltd. Approves 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on May 26, 2022

Anshan Hifichem Co., Ltd. Approves Cash Dividend

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Anshan Hifichem Co., Ltd. Proposes Final Dividend for the Year 2021

Third quarter 2021 earnings released: EPS CN¥0.094 (vs CN¥0.12 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.28 in 2Q 2020)

Investor sentiment deteriorated over the past week

Anshan Hifichem Co., Ltd. (SZSE:300758) agreed to acquire additional 29% stake in Shaoxing Shangyu Xinli Chemical Industry Co., Ltd. from Chen Jianxin for approximately CNY 150 million.

Full year 2020 earnings released: EPS CN¥0.91 (vs CN¥0.59 in FY 2019)

New 90-day low: CN¥21.86

New 90-day low: CN¥23.42

Market bids up stock over the past week

New 90-day low: CN¥23.45

Third quarter earnings released

Market bids up stock over the past week

Earnings released

Anshan Hifichem Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad